The curative effect, mechanism and macro-micro-meso standard establishment of the precise treatment Reyu Duju, Maizhi Luobi of cerebral small vessel disease

Fudan University0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•(1) The imaging performance on MRI includes one of the following manifestations: recent small subcortical infarcts, lacuna, white matter hyperintensity, microhemorrhage,brain atrophy and enlarged perivascular spaces.
•(2) Meet the heat depression poison gathering Pulse stagnation syndrome of traditional Chinese medicine diagnostic standards in the early stage of cerebral small vessel disease.
•(3) Aged 18-80 years, male or female.
•(4) Understand, agree to participate in this study and sign an informed consent.

•(1) Large cerebral artery stenosis >= 50%.
•(2) Any hearing or visual impairment that can disturb efficient cognitive evaluation of the patient.
•(3) Massive cerebral infartion from cardioembolic source.
•(4) Any other white matter disease (i.e., multiple sclerosis, metabolic encephalopathy,toxic encephalopathy or multiple intracranial vasculitis).
•(5) Severe osteoarthritis and severe joint and muscle pain that may limit the patient's movement. Complicated with severe heart, liver, kidney, blood system and other diseases, or other serious primary diseases, mental illness.
•(6) Allergy to drugs in treatment programmes.
•(7) Pregnant or lactating women.
•(8) Patients who had participated in or were participating in other clinical trial the month before entering the group, or patients who had taken or were taking other medications for cerebral small vessel disease or Chinese herbal medicine with the same composition or the same effect as the tested Chinese herbal compound the month before entering the group.

发起方